Matthew Hamilton Rosenberg’s Catalyst Pharmaceutical CPRX Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4	Closed	-$67	–	870
2023 Q4	$67	Hold	4	–	–	﹤0.01%	889
2023 Q3	$47	Hold	4	–	–	﹤0.01%	914
2023 Q2	$54	Buy	+4	New	+$58	﹤0.01%	933

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Matthew Hamilton Rosenberg's CPRX Position: Q1 2024 in Review

Matthew Hamilton Rosenberg sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 4 shares — an estimated $67 sold.

Matthew Hamilton Rosenberg first reported a position in CPRX in Q2 2023 and held it in 3 quarters. The position peaked at $67 in Q4 2023. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

Matthew Hamilton Rosenberg reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Matthew Hamilton Rosenberg sold 4 Catalyst Pharmaceutical shares in Q1 2024, an estimated $67.
Matthew Hamilton Rosenberg first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 3 quarters.
Matthew Hamilton Rosenberg's Catalyst Pharmaceutical position peaked at $67 in Q4 2023.
269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q1 2024, filed 22 Apr 2024.